Ticker Details
Iovance Biotherapeutics, Inc. Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date:	October 23, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.05B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.73%
Avg Daily Range (30 D):	$0.26 | 5.49%
Avg Daily Range (90 D):	$0.18 | 4.33%

Institutional Daily Volume
Avg Daily Volume:	4.56M
Avg Daily Volume (30 D):	17.02M
Avg Daily Volume (90 D):	14.72M

Trade Size
Avg Trade Size (Sh.):	198
Avg Trade Size (Sh.) (30 D):	315
Avg Trade Size (Sh.) (90 D):	326

Institutional Trades
Total Institutional Trades:	5,735
Avg Institutional Trade:	$2.54M
Avg Institutional Trade (30 D):	$2.18M
Avg Institutional Trade (90 D):	$2.63M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.91M
Avg Closing Trade (30 D):	$4.33M
Avg Closing Trade (90 D):	$4.48M
Avg Closing Volume:	425.27K

News

Aug 10, 2026 @ 7:29 PM Iovance Biotherapeutics Stock Soars After the Comp... Source: David Jagielski, Cpa

Jul 17, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

Jun 23, 2026 @ 11:33 PM Amgen vs. Iovance Biotherapeutics: Which Healthcar... Source: Sara Appino

Jun 19, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

May 22, 2026 @ 9:15 PM Iovance Biotherapeutics Reports Inducement Grants ... Source: Na

Financials
	TTM	Q1 2026	Q3 2025
Basic EPS	$-.11	$-.19	$-.25
Diluted EPS	$-.11	$-.19
Revenue	$99.31M	$71.43M	$67.46M
Gross Profit	$55.72M	$28.93M	$28.98M
Net Income / Loss	$-47.32M	$-79.05M	$-91.25M
Operating Income / Loss	$-51.91M	$-81.04M	$-94.9M
Cost of Revenue	$43.6M	$42.5M	$38.48M
Net Cash Flow	$-85.73M	$33.44M	$25.69M
PE Ratio

Splits
Sep 26, 2013	1:100
Apr 06, 2010	24:1